Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBlue Cross Blue Shield NE Prenatal Testing Prior A…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - NebraskaPolicy M.69

    MA Reproductive Testing: Prenatal Diagnosis (Preauthorization Required)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Nebraska Policy M.69 alerts

    Get alerted when Policy M.69 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, preauthorization expectations, and coverage criteria for prenatal diagnostic genetic tests (CMA, exome, genome, targeted panels) via invasive sampling and for chromosomal microarray on products of conception; applies to Blue Cross Blue Shield - Nebraska members.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Reproductive Testing: Prenatal Diagnosis (Preauthorization Required)
    Policy CodePolicy M.69
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionSubmit preauthorization for listed prenatal diagnostic genetic tests and include required procedure/diagnosis code pair and counseling documentation when specified.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    I - IIIMajor policy sections
    05-01-2026Original Effective Date
    requiredPreauthorization
    30+Procedure codes enumerated
    6–35%Exome diagnostic yield

    Coverage Criteria for Prenatal and Pregnancy-loss Genetic Testing

    inv-01: Prenatal CMA — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Prenatal CMA criteria: A. The member has received counseling regarding the benefits and limitations of prenatal screening and diagnostic testing (including chromosome microarray via amniocentesis, CVS, or PUBS) AND B. The member is NOT simultaneously undergoing karyotype analysis.

    Chromosomal microarray analysis for prenatal diagnosis is considered not reasonable and necessary for all other indications.

    inv-02: Prenatal Exome Sequencing — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Prenatal exome criteria: A. The member's current pregnancy has had a karyotype and/or microarray performed and the results were negative/normal AND B. Alternate etiologies have been considered and ruled out when possible (examples: environmental exposure, injury, infection, maternal condition) AND C. The member's current pregnancy has either: (1) non-immune hydrops fetalis OR (2) two or more major malformations on ultrasound affecting different organ systems.

    Prenatal exome sequencing is considered not reasonable and necessary for all other conditions; pretest counseling by a genetics professional and rapid laboratory turnaround time are recommended.

    inv-03: Prenatal Genome Sequencing — 1 top-level node

    Prenatal genome criteria: Prenatal diagnosis via genome sequencing (amniocentesis, CVS, or PUBS) is considered not reasonable and necessary for all indications.

    No indications covered.

    inv-04: Pregnancy Loss (POC) CMA — Covered when ONE of the following are met AND counseling provided

    Covered when ONE of the following is met AND counseling provided

    POC CMA criteria: A. The member has a history of recurrent pregnancy loss (two or more failed clinical pregnancies) OR B. The member has a pregnancy loss at or greater than 20 weeks of gestation (intrauterine fetal demise or stillbirth) AND the member has received counseling regarding the benefits and limitations of chromosome microarray analysis on products of conception.

    Chromosomal microarray analysis on POC is considered not reasonable and necessary for all other indications.

    inv-05: Noonan Spectrum Disorders / RASopathies — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Noonan panel criteria: A. The member's current pregnancy has a normal karyotype and/or microarray AND B. Either (1) an ultrasound finding of increased nuchal translucency or cystic hygroma of at least 5.0 mm in the first trimester, OR (2) an increased nuchal translucency of at least 3.0 mm PLUS one additional ultrasound finding (distended jugular lymph sacs, hydrops fetalis, polyhydramnios, pleural effusion, or specified cardiac defects).

    Prenatal testing for Noonan spectrum disorders is considered not reasonable and necessary for all other indications.

    inv-06: Skeletal Dysplasias — Covered when ALL of the following are met

    Covered when ALL of the following are met

    Skeletal dysplasia criteria: A. The member’s current pregnancy has any of the following ultrasound findings: long bones less than the 5th percentile, poor mineralization of the calvarium, fractures of long bones (particularly femora), bent/bowed bones, poor mineralization of the vertebrae, absent/hypoplastic scapula, or equinovarus; AND B. The panel being ordered includes at minimum the genes COL1A1, COL1A2, COL2A1, and FGFR3.

    Prenatal skeletal dysplasia panels are considered not reasonable and necessary for all other indications.

    inv-07: Medically Necessary Indications (society-aligned) — Covered when aligned with professional society recommendations and clinical indications:

    Covered when aligned with professional society recommendations and clinical indications:

    CMA for invasive testing: Chromosomal microarray should be offered to any patient choosing to undergo invasive diagnostic testing and is the primary test when fetal structural abnormalities are detected.

    ACOG and ACOG-SMFM guidance support CMA replacing karyotype for structural anomalies.

    Karyotype first when specific aneuploidy suspected: If features suggest a specific aneuploidy, karyotype with or without FISH may be offered before CMA.

    ACOG practice bulletin notes this exception.

    Exome sequencing (ES): Exome sequencing may be considered for fetuses with ultrasound anomalies when CMA and karyotype are non-diagnostic; when a specific diagnosis is suspected, single-gene testing or a targeted panel is preferred. Genetics pretest and post-test counseling and rapid turnaround times are recommended where relevant.

    ACMG points to consider and society statements referenced.

    Prenatal genome sequencing (whole-genome sequencing performed on fetal samples obtained via amniocentesis, CVS, or PUBS) is excluded for all indications under this policy and is considered not reasonable and necessary (no clinical circumstances are listed where prenatal genome sequencing is covered).

    This exclusion aligns with the policy text which explicitly states that prenatal genome sequencing is considered not reasonable and necessary for all indications.

    Routine use of whole-genome sequencing (WGS) or whole-exome sequencing (WES) for prenatal diagnosis is not recommended outside the context of clinical trials until sufficient peer‑reviewed data and validation studies are published. Professional society guidance cited by the policy (ACOG/SMFM and ISPD) supports limiting routine prenatal WES/WGS to research or select validated clinical contexts.

    Providers should therefore consider WGS/WES prenatally only within research protocols or when supported by specific, validated clinical indications described elsewhere in this policy.

    There are no additional exclusions or exception statements listed in this section beyond those explicitly described for prenatal genome sequencing and routine prenatal WES/WGS use.

    Each coverage section in this policy defines specific clinical indications that meet medical necessity and expressly indicates that testing is not reasonable and necessary for other indications outside those listed. Examples include prenatal CMA, prenatal exome sequencing, prenatal genome sequencing, CMA on products of conception (POC), Noonan/RASopathy panels, and skeletal dysplasia panels.

    Prior authorization and the specific clinical criteria must be met for coverage; tests performed for indications not enumerated in the applicable section are subject to denial as not reasonable and necessary.

    The policy references ACOG/SMFM and ISPD guidance which advise against routine clinical use of WGS/WES for prenatal diagnosis outside of research or carefully validated settings. Consequently, routine deployment of WGS/WES in prenatal care without a research context or validated indication is considered inappropriate per those society statements.

    In the portions of the source cited for coding and general statements, there are no additional explicit sections labeled ‘not medically necessary’ beyond the policy’s per-section statements that tests are not reasonable and necessary for indications outside the listed criteria.

    Procedure and Billing Codes

    Referenced CPT/HCPCS codes in policy tablesmixed
    81228Listed in CMA and pregnancy loss CMA reference table
    81229Listed in CMA and pregnancy loss CMA reference table
    81265Listed in multiple sequencing and panels reference table
    81349Listed in CMA reference table
    81479Unlisted molecular pathology code referenced in tables
    0469UIriSight CNV Analysis - Prenatal (Variantyx) referenced
    81415Exome sequencing code referenced for prenatal exome
    81416Exome sequencing code referenced for prenatal exome
    81425Whole genome sequencing code referenced
    81426Whole genome sequencing code referenced
    1–10 of 13
    1/2
    Referenced CPT/HCPCS codes (alternate source rows)mixed
    No codes listed
    PLA/UCSD/Proprietary sequencing codes (group 1)HCPCS
    0212URARE DS WHL GEN&MITOCHDRL DNA SEQ ALYS PROBAND
    0213URARE DS WHL GEN&MITOCHDRL DNA SEQ ALYS EA CMPRTR
    0214URARE DS WHL XOM
    0215URARE DS WHL XOM
    0265URARE DO WHL GENOME&MITOCHDRL DNA SEQ ALYS
    PLA/rapid genome sequencing codes (group 2)HCPCS
    0335URARE DISEASES WHOLE GENOME SEQ ALYS FETAL SAMPLE
    0336URARE DISEASES WHOLE GENOME SEQ ALYS BLOOD/SALIVA
    0425UGENOME RAPID SEQ ANALYSIS EACH COMPARATOR GENOME
    0426UGENOME ULTRA-RAPID SEQUENCE ANALYSIS
    PLA/whole genome sequencing (fetal-focused)HCPCS
    0469URARE DS WHL GENOM SEQ ALYS CHRMOML ABNR FTL SAMP
    0532URARE DS RAPID WHL GEN&MITOCHDRL DNA SEQ SNV SLV
    0567URARE DS WHL GENOME SEQ ALYS SRS&LRS SNVS INDELS
    PLA/rapid whole genome sequencing (companion/comparator)HCPCS
    0582URARE DS RPD WHL GEN DNA SEQ SNVS INDELS VARIANTS
    0583URARE DS RPD WHL GEN CMPTR DNA SEQ VRNTS PROBAND
    CPT molecular and cytogenomic procedure codesCPTCovered
    81210BRAF GENE ANALYSIS V600E VARIANT
    81228CYTOGENOM CONST MICROARRAY COPY NUMBER VARIANTS
    81229CYTOGENOM CONST MICROARRAY COPY NUMBER&SNP VAR
    81265COMPARATIVE ANAL STR MARKERS PATIENT&COMP SPEC
    81266COMPARATIVE ANAL STR MARKERS EA ADDL SPECIMEN
    81349CYTOG ALYS CHRMOML ABNOR LOW-PASS SEQ ALYS
    81404MOLECULAR PATHOLOGY PROCEDURE LEVEL 5
    PLA/Proprietary molecular sequencing codesCPT
    0582URARE DS RPD WHL GEN DNA SEQ SNVS INDELS VARIANTS
    0583URARE DS RPD WHL GEN CMPTR DNA SEQ VRNTS PROBAND
    Cytogenomic and comparative analysis codesCPTCovered
    81210BRAF GENE ANALYSIS V600E VARIANT
    81228CYTOGENOM CONST MICROARRAY COPY NUMBER VARIANTS
    81229CYTOGENOM CONST MICROARRAY COPY NUMBER&SNP VAR
    81265COMPARATIVE ANAL STR MARKERS PATIENT&COMP SPEC
    81266COMPARATIVE ANAL STR MARKERS EA ADDL SPECIMEN
    81349CYTOG ALYS CHRMOML ABNOR LOW-PASS SEQ ALYS
    Molecular pathology levels, exome/genome, panels and unlisted codesCPTCovered
    81404MOLECULAR PATHOLOGY PROCEDURE LEVEL 5
    81405MOLECULAR PATHOLOGY PROCEDURE LEVEL 6
    81406MOLECULAR PATHOLOGY PROCEDURE LEVEL 7
    81407MOLECULAR PATHOLOGY PROCEDURE LEVEL 8
    81408MOLECULAR PATHOLOGY PROCEDURE LEVEL 9
    81415EXOME SEQUENCE ANALYSIS
    81416EXOME SEQUENCE ANALYSIS EACH COMPARATOR EXOME
    81425GENOME SEQUENCE ANALYSIS
    81426GENOME SEQUENCE ANALYSIS EACH COMPARATOR GENOME
    81442NOONAN SPECTRUM DISORDERS GEN SEQ ANALYS 12 GEN
    1–10 of 11
    1/2
    inv-23: Nuchal translucency — thresholds
    ThresholdNuchal translucency ≥ 5.0 mm (single criterion)
    Alternate thresholdNuchal translucency ≥ 3.0 mm PLUS one additional ultrasound finding (distended JLS, hydrops fetalis, polyhydramnios, pleural effusion, or specified cardiac defects)
    ContextApplied to prenatal diagnosis for Noonan spectrum disorders/RASopathies when karyotype/microarray is normal
    inv-24: Long bones percentile
    Threshold

    Provider Requirements, Preauthorization, and Documentation

    Prior Authorization

    Preauthorization required for prenatal diagnostic genetic tests

    Submit preauthorization for any prenatal diagnostic genetic test listed in this policy; include the procedure code and corresponding diagnosis code pair when requesting review. The policy title and header designate these tests as "Preauthorization Required."

    • Quick Code Search requires entering a procedure code then a diagnosis code and clicking "Add Code Pair."
    • If the codes are listed in this policy the Quick Code Search will display a dropdown to assist.
    Prior Authorization

    Preauthorization required for listed genetic testing codes

    Preauthorization is required for sequencing, microarray, and selected molecular procedure codes when used for prenatal diagnosis or pregnancy loss evaluation; include the specific CPT/PLA/HCPCS code(s) on the authorization request.

    • Examples of listed procedure codes include CPT/PLA/HCPCS codes such as 0212U, 0213U, 0214U, 0215U, 0265U, 0335U, 0336U, 0425U, 0426U, 0469U, 0532U, 0567U, 0582U, 0583U, 81210, 81228, 81229, 81265, and 81404 (see policy Code section).

    Background and Rationale

    Prenatal diagnostic genetic testing (including chromosomal microarray analysis, exome sequencing, genome sequencing, and targeted panels) is used to identify fetal genetic conditions in pregnancies at increased risk and to evaluate causes of pregnancy loss. The policy requires counseling where specified and recommends CMA as the primary test when structural fetal anomalies are present; exome sequencing may be considered when CMA/karyotype are non-diagnostic and specific criteria (such as non-immune hydrops fetalis or multiple major malformations) are met.

    Genetic counseling is emphasized prior to testing, and preauthorization is required for listed tests and associated CPT/HCPCS codes.

    Definitions and Test Descriptions

    inv-43: Amniocentesis — definition and use
    DefinitionAmniocentesis: removal of amniotic fluid from the uterus for prenatal diagnostic testing
    Typical usesObtain fetal DNA for CMA, karyotype, single-gene or sequencing testing via an invasive sample
    When performedUsed when invasive diagnostic testing is indicated (e.g., abnormal ultrasound findings or positive screening)
    inv-44: Chorionic Villus Sampling (CVS) — definition and use
    DefinitionChorionic villus sampling (CVS): removal of chorionic villi from the placenta for prenatal diagnostic testing
    Typical usesObtain placental tissue for fetal genetic testing (karyotype, CMA, molecular testing) earlier in pregnancy than amniocentesis

    Policy Revision History

    2026-05-01policy_effectiveLatest

    Policy M.69 original effective date established.

    2026-01-28policy_review

    Policy underwent last review on 2026-01-28 prior to effective date.

    Policy Summary
    PayerBlue Cross Blue Shield - Nebraska
    PolicyMA Reproductive Testing: Prenatal Diagnosis (Preauthorization Required)
    Policy CodePolicy M.69
    Change TypeNo material change
    Effective DateMay 1, 2026
    Next Review DateJan 1, 202743d
    Key ActionSubmit preauthorization for listed prenatal diagnostic genetic tests and include required procedure/diagnosis code pair and counseling documentation when specified.
    SourceLink
    On This Page
    Coverage Criteria for Prenatal and Pregnancy-loss Genetic TestingProcedure and Billing CodesProvider Requirements, Preauthorization, and DocumentationBackground and RationaleDefinitions and Test DescriptionsPolicy Revision History
    WGS/WES research context: Routine use of whole-genome or whole-exome sequencing for prenatal diagnosis is not recommended outside clinical trials until sufficient validation data are published; limited clinical use may be considered in select contexts.

    ISPD and ACOG/SMFM statements indicate limited routine use.

    CMA for pregnancy loss: Chromosomal microarray analysis of fetal tissue (POC) is recommended for evaluation of intrauterine fetal death or stillbirth when further cytogenetic analysis is desired because of higher likelihood of obtaining results compared with conventional karyotype.

    ACOG/SMFM committee opinion and ASRM literature support CMA for products of conception.

    Fetal long bones less than 5th percentile
    Associated ultrasound findingsPoor calvarial mineralization, long bone fractures, bent/bowed bones, poor vertebral mineralization, absent/hypoplastic scapula, equinovarus
    ContextCriterion for offering prenatal skeletal dysplasia panel via amniocentesis, CVS, or PUBS
    inv-25: Enlarged nuchal translucency (NT)
    Enlarged NT definitionNuchal translucency (NT) ≥ 3.0 mm or above the 99th percentile for crown–rump length
    Higher-risk thresholdTesting recommended at NT ≥ 5.0 mm (Stuurman cohort and Noonan panel criteria)
    Clinical implicationEnlarged NT supports consideration of Noonan spectrum testing after negative karyotype/microarray
    inv-26: Long bone measurement threshold for skeletal dysplasia evaluation
    Primary thresholdLong bones at or ≤ 5th centile
    Alternative thresholdLong bones > 3 standard deviations below the mean
    ActionFetuses meeting these measurements should be evaluated in centers experienced in skeletal dysplasia recognition
    Prior Authorization

    Preauthorization required for listed prenatal diagnostic codes

    Preauthorization must be obtained for the prenatal diagnostic and molecular pathology tests and billing codes enumerated in the policy's code tables before testing is performed.

    • Covered/listed codes include cytogenomic microarray (81228, 81229, 81349) and molecular pathology/exome/genome codes (81404, 81415, 81416, 81425, 81426, 81479, etc.).
    Step Therapy

    Required prior testing steps before approval

    Follow the policy's required sequencing of testing: exome sequencing requests must document prior negative/normal karyotype and/or microarray results; authorization is contingent on those prior tests having been performed and reviewed.

    • Prenatal exome: member's current pregnancy must have had karyotype and/or microarray performed with negative/normal results before exome is considered.
    • Policy language indicates CMA is primary for structural anomalies and exome is considered when CMA/karyotype are non-diagnostic.
    Step Therapy

    Preferred testing sequence for fetal structural anomalies

    When fetal structural anomalies are detected, submit CMA as the primary diagnostic test (it can replace conventional karyotype); if a specific aneuploidy is suspected document why karyotype (with or without FISH) is being performed first.

    • ACOG recommends offering CMA to any patient undergoing invasive diagnostic testing and as the primary test when fetal structural abnormalities are detected.
    • The policy allows karyotype first if features suggest a specific aneuploidy.
    Note
    Documentation Required

    Document counseling about benefits and limitations

    Document that the member received counseling about the benefits and limitations of prenatal screening and diagnostic testing (including CMA) when counseling is specified; include counseling notes with the preauthorization submission where applicable.

    • Policy criteria require that the member has received counseling regarding benefits and limitations for prenatal CMA and for CMA on products of conception.
    • Counseling is a stated coverage criterion and is required for consideration of CMA in prenatal and POC settings.
    Documentation Required

    Genetics counseling and laboratory turnaround documentation

    For fetal exome sequencing, include documentation of pretest counseling by a genetics professional and note laboratory turnaround-time expectations; post-test counseling should be arranged and documented regardless of result.

    • ACMG guidance recommends pretest counseling by a genetics professional and that laboratories offering prenatal ES have clearly defined rapid turnaround times.
    • Post-test counseling by individuals with relevant expertise is recommended regardless of test result.
    Prior Authorization

    Include guideline references with prior authorization

    Submit preauthorization requests with clinical documentation referencing guideline support where relevant (e.g., ACOG practice bulletins and ACOG–SMFM committee opinions cited in the policy) to support medical necessity determinations.

    • Policy references ACOG Practice Bulletin No.162 and ACOG–SMFM Committee Opinion No.682 among literature cited in the References section.
    Denial Risk

    Denial risk: prenatal CMA outside criteria

    CMA for prenatal diagnosis is considered not reasonable and necessary for indications that do not meet the policy criteria (member must have counseling and must not be simultaneously undergoing karyotype analysis).

    • Policy states CMA is considered reasonable and necessary only when counseling is provided and the member is not simultaneously undergoing karyotype; all other indications are not reasonable and necessary.
    Denial Risk

    Denial risk: prenatal exome outside specified indications

    Prenatal exome sequencing will be denied if requested for conditions outside the specified criteria; authorization requires documentation of prior negative/normal karyotype and/or microarray, consideration of alternate etiologies, and qualifying fetal findings.

    • Covered indications require prior negative/normal karyotype/microarray and either non-immune hydrops fetalis or two or more major malformations on ultrasound affecting different organ systems.
    • Exome sequencing is not reasonable and necessary for all other conditions.
    Denial Risk

    Denial risk: prenatal genome sequencing (all indications)

    Prenatal genome sequencing is considered not reasonable and necessary for all indications and authorization requests for prenatal genome sequencing will be denied.

    • Policy explicitly states prenatal genome sequencing is not reasonable and necessary for any indication.
    Denial Risk

    Denial risk: POC CMA outside criteria

    Chromosomal microarray analysis on products of conception (POC) will be denied if the request does not meet policy criteria; covered POC CMA requires a history of recurrent pregnancy loss or a loss at ≥20 weeks and documentation that counseling was provided.

    • Policy requires either recurrent pregnancy loss or pregnancy loss at or ≥20 weeks gestation plus counseling regarding benefits and limitations of CMA on POC.
    • POC CMA is not reasonable and necessary for all other indications.
    Billing Rule

    Include procedure + diagnosis code pair on authorization

    Ensure the preauthorization request includes both the specific procedure code and the diagnosis code pair; failure to submit both may prevent the Quick Code Search from assisting and could delay review or lead to hold/denial.

    • Quick Code Search workflow: enter procedure code, then diagnosis code, then click "Add Code Pair."
    • The policy warns that omission of the diagnosis/procedure pair can impede automated assistance.
    Prior Authorization

    Preauthorization requirement (policy header)

    Tests listed in the policy header require preauthorization prior to performance; do not proceed with testing without an approved authorization.

    • Policy title includes the phrase "Preauthorization Required," establishing the preauthorization expectation for the listed tests.
    Note

    Background: counseling and test purpose

    Background: prenatal diagnostic genetic tests (CMA, exome, genome, targeted panels) are used to identify fetal genetic conditions in pregnancies at increased risk; genetic counseling is strongly recommended prior to testing.

    • Policy description emphasizes joint decision-making between patient and clinician and strongly recommends genetic counseling.
    When performedAn option for invasive diagnostic testing when early prenatal diagnosis is desired
    inv-45: Percutaneous Umbilical Cord Blood Sampling (PUBS) — definition and use
    DefinitionPercutaneous Umbilical Cord Blood Sampling (PUBS): extraction of fetal blood from the umbilical cord vein for diagnostic testing
    Typical usesObtain fetal blood for genetic or metabolic testing when other sources are not sufficient
    Clinical contextUsed as an invasive diagnostic route alongside amniocentesis or CVS when indicated
    inv-46: Major malformations — definition and examples
    DefinitionMajor malformations: structural defects with significant effect on function or appearance, possibly lethal or causing severe morbidity
    Examples by systemGenitourinary (renal agenesis), Cardiovascular (complex heart malformations), Musculoskeletal (osteogenesis imperfecta), CNS (anencephaly), Body wall (omphalocele), Respiratory (cystic adenomatoid malformation)
    Use in policyPresence of two or more major malformations across different organ systems can meet criteria for prenatal exome sequencing
    inv-47: Recurrent pregnancy loss (RPL) — definition
    DefinitionRecurrent pregnancy loss (RPL): two or more failed clinical pregnancies (includes current loss if applicable)
    Policy useRPL is an indication for chromosomal microarray analysis on products of conception when counseling is provided
    ContextUsed to determine eligibility for POC CMA coverage under the policy
    inv-48: Chromosomal microarray analysis (CMA) — definition and recommendation as primary test for structural anomalies
    DefinitionChromosomal microarray analysis (CMA): genome-wide microarray to detect copy number variants and SNPs
    RecommendationRecommended as the primary test for fetuses with structural anomalies and offered to patients undergoing invasive diagnostic testing
    Use for pregnancy lossRecommended for evaluation of fetal tissue (amniotic fluid, placenta, POC) after intrauterine fetal death or stillbirth when further cytogenetic analysis is desired
    inv-49: Exome sequencing (ES) / Whole-exome sequencing (WES) — definition and context of use
    DefinitionExome sequencing (ES/WES): sequencing of coding regions to detect single-gene causes of disease
    Context of useMay be considered for fetuses with ultrasound anomalies when CMA and karyotype are non-diagnostic; single-gene or targeted panels preferred when a specific diagnosis is suspected
    Counseling and turnaroundPretest and post-test counseling by genetics professionals recommended; laboratories should define rapid turnaround times for prenatal ES
    inv-50: Whole genome sequencing (WGS) — definition and current recommendation status
    DefinitionWhole genome sequencing (WGS): comprehensive sequencing of the genome
    Recommendation statusCurrently not recommended for routine prenatal diagnosis outside research or select clinical contexts until further validation
    Evidence contextSome studies suggest comparable diagnostic yield to CMA plus WES but more prospective validation is needed
    inv-51: Comparator exome/genome — definition
    DefinitionComparator exome/genome: sequencing of additional family members (e.g., parents, siblings) listed separately in coding as comparator specimens
    PurposeUsed to aid interpretation of variants identified in the proband by providing familial context
    Billing noteComparator sequencing is reported using separate codes (e.g., 81416 for exome comparator, 81426 for genome comparator)